Antagonistic analogs of GHRH inhibit growth of various human cancers both in vivo and in vitro. To elucidate the mechanism of direct action of the antagonistic analogs of GHRH on tumor cells, cultured human cancer cells were exposed to GHRH, vasoactive intestinal peptide (VIP), secretin, glucagon, neuropeptide-Y (NPY), pituitary adenylate cyclase-activating peptide (PACAP), and VIP analogs in a superfusion system, and changes in cAMP and IGF-II release from the cells were measured. Various human cancer cell lines, such as mammary (MDA-MB-468 and ZR-75-1), prostatic (PC-3), pancreatic (SW-1990 and Capan-2), ovarian (OV-1063), and colorectal (LoVo) responded to pulsatile stimuli with GHRH (0·5-20 nM), VIP (0·02-10 nM), and PACAP-38 (0·05-5 nM) with a rapid, transient increase in cAMP release from the cells. The VIP antagonist, PG-97-269, and the adenylate cyclase inhibitor, MDL-12330A, but not SQ-22536 or pertussis toxin, blocked the cAMP responses to these peptides. Stimulation of the cells with 100 nM secretin, glucagon or NPY did not alter the cAMP release. Our results suggest that GHRH receptors different from the type expressed in the pituitary are involved in mediating these effects. As cAMP is a potent second messenger controlling a wide variety of intracellular functions, including those required for cell growth, our results indicate that GHRH might have a direct stimulatory effect on growth of human cancers. Blockade of the autocrine/paracrine action of GHRH with its antagonistic analogs may provide a new approach to tumor control.
Introduction
Antagonistic analogs of growth hormone-releasing hormone (GHRH) developed in our laboratory (Zarandi et al. 1994 (Zarandi et al. , 1997 exhibit potent inhibitory effects on the growth of various human cancers (Pinski et al. 1995 , Jungwirth et al. 1997a , b, Schally et al. 1998 . Insulin-like growth factors (IGFs)-I and -II are required for proliferation of most neoplasms (Daughaday 1990 , Macaulay 1992 , Westley & May 1995 , Toretsky & Helman 1996 . Antagonistic analogs of GHRH inhibit the growth hormone-releasing hormone-growth hormone (GH)-IGF-I axis, thus reducing the level of hepatic IGF-I (Pinski et al. 1995 , Schally et al. 1998 , and also suppress autocrine IGF-II secretion by many cancer cells (Jungwirth et al. 1997a, b) . We recently reported that antagonistic analogs of GHRH (MZ-4-71 and MZ-1-156) inhibited growth, IGF-II production and expression of IGF-II mRNA of various human cancer cell lines in vitro in tissue culture (Csernus et al. 1999a) . It was suggested that these analogs interfere with the autocrine regulatory pathway of IGF-II by decreasing the IGF-II production of cancer cells (Csernus et al. 1999a) . The mechanism of this action, however, remains to be clarified. Several possibilities could be considered. The antagonistic analogs of GHRH may block a direct stimulatory effect of GHRH on the cancer cells. The hypothalamus is considered to be the primary source of GHRH. Hypothalamic GHRH is transported by portal circulation to the anterior pituitary, where it stimulates the GH cells, its primary target. Subsequently, GHRH becomes diluted in the general circulation, to a subphysiological concentration (Plotsky & Vale 1985) , and is also inactivated rapidly by dipeptidases, so that its effective half-life in circulation is only about 1 min (Frohman et al. 1989b) . Consequently, no significant extrapituitary functions of hypothalamic GHRH can be expected. Although GHRH is considered to be primarily a hypothalamic hormone, it is also found in several extrahypothalamic tissues, tumor specimens and cancer cell lines (Shibasaki et al. 1984 , Thorner et al. 1985 , Frohman et al. 1986 , Losa et al. 1990 , Ciampani et al. 1992 , Kahan et al. 1999 .
Expression of mRNA for GHRH, GHRH binding sites and GHRH receptor mRNA were also shown to be present in various tissues and cancers (Frohman et al. 1989a , Stephanou et al. 1991 , Bagnato et al. 1992 . On the basis of these findings, it may be reasonable to assume that GHRH could exert local paracrine or autocrine regulatory functions in various tissues. Antagonistic analogs of GHRH might interfere with this local regulation.
GHRH shows considerable structural homology with several gastrointestinal peptides, such as vasoactive intestinal polypeptide (VIP), secretin, glucagon, cholecystokinin and neuropeptide-Y (NPY). Recently-discovered pituitary adenylate cyclase-activating polypeptide (PACAP) also belongs to this group (Miyata et al. 1989) . Another common feature of these peptide hormones is that their receptors also display a major sequence identity. All the receptors that can bind these hormones with considerable cross-activity are members of the seven transmembranespanning receptor superfamily (Laburthe et al. 1996) . These peptides, especially GHRH, VIP and PACAP, exhibit similar effect on several organs, including testis (Csaba et al. 1997) , gall bladder (Parkman et al. 1997a) , pyloric muscle (Parkman et al. 1997b) , or pancreas (Inagaki et al. 1996) , apparently mediated by common receptors. Various findings indicate that receptors of peptide hormones belonging to the GHRH-VIP family are present on colon (Ogasawara et al. 1997) , pancreatic (Schafer et al. 1996) , lung (Davidson et al. 1996) , prostate (Gkonos et al. 1996) and breast (Zia et al. 1996) cancers and mesenchymal (Reubi et al. 1996) and neural (Lelievre et al. 1996 , Vertongen et al. 1996 tumors, and are involved in the proliferation of these tumors.
Because of the expected cross-activity of the GHRH antagonistic analogs with the different receptors of the GHRH-VIP-PACAP family, it seemed appropriate for us also to investigate the effects of other VIP-related peptides on tumor cells. The dispersed cell superfusion system (Csernus & Schally 1991) proved to be a valuable tool with which to evaluate dynamic changes in receptor functions on isolated cells. As most of the receptors in this family are coupled to adenylate cyclase, changes in cAMP production of the cells were used as an index of receptor activity. The measurement of cAMP production in a superfusion system has been useful for investigating intracellular mechanisms of hormone release from explanted endocrine cells (Horvath et al. 1995a , b, Rekasi et al. 1998 . The role of cAMP in the control of metabolism of tumor cells has been studied since the early 1970s (Martin et al. 1976) . cAMP regulation of the growth of various tumors, such as the MCF-7 breast cancer cell line (Cho-Chung et al. 1981) , carcinogen-induced mammary tumors (Ip & Dao 1980) , and non-small-cell lung cancer (Lee et al. 1990 ) has been described, and cAMP has been proposed as a biochemical marker for malignancy of colon cancer cells (Nelson & Holian 1988) . The effects of GHRH antagonists on dynamic release of cAMP in various cancer cell lines have been reported elsewhere (Csernus et al. 1999b) . In the present study, we measured dynamic changes in cAMP production of human cancer cell lines in response to related peptide hormones and to various drugs that affect the intracellular signal transduction system. (Gourlet et al. 1997a, b) . Forskolin, MDL-12330A [cis-N-(2-phenylcyclopentyl) azacyclotridec-1-en-2-amine], SQ-22536 and PACAP-38 were obtained from Calbiochem (La Jolla, CA, USA). Secretin (S-7147), glucagon (G-9154), NPY (N-5017), pertussis toxin (PTX, P-0317), BSA (A-7888), medium-199 (M-5017) and, unless otherwise indicated, other organic and inorganic chemicals were purchased from Sigma Chemical Co. (St Louis, MO, USA).
Materials and Methods

Chemicals
Tissue culture
Tumor cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The media for routine culture (Gibco-Brl, Grand Island, NY, USA) varied, depending on the requirements of the cell lines: RPMI-1640 (RPMI)+10% fetal bovine serum (FBS) were used for Capan-2, DU-145, H-23 and H-69 cells; RPMI+5% FBS for PC-3 cells; F12+20% FBS for LoVo cells; Improved Minimal Essential Medium (IMEM)+10% FBS for MDA-MB-468 cells; L15+10% FBS for SW-1990 cells; RPMI+10% FBS supplemented with pyruvate and glucose for ZR-75-1 cells; and, RPMI+10% FBS+pyruvate and MEM vitamins for OV-1063 cells. The cultures were maintained in a humidified atmosphere containing 5% CO 2 /95% air at 37 C. The cells were passaged weekly and routinely monitored for the presence of mycoplasma using a test kit from Boehringer Mannheim (Indianapolis, IN, USA). Before the superfusion experiments, cells at about 70% confluence stage were harvested by a brief incubation with 0·25% trypsin-EDTA solution (Gibco), centrifuged, resuspended in 1·5 ml medium and applied to the superfusion columns.
Superfusion
Superfusion analysis of cultured human cancer cells was performed in a system similar to that described earlier for studying dispersed anterior pituitary cells (Csernus & Schally 1991) . Briefly: cultured tumor cells were harvested, resuspended in 1·5 ml medium and the cells, mixed with Sephadex G-10, were transferred onto superfusion columns (5-6 10 6 cells each). Medium-199-based tissue culture medium, supplemented with 1 g/l BSA, 50 mg/l penicillin-G and 87 mg/l gentamicin, was perfused through the columns at a rate of 20 ml/h. After an overnight recovery period, 2 ml (6 min) fractions were collected from the effluent media. The cells were periodically exposed to test compounds that were dissolved in fresh medium immediately before application. Unless otherwise indicated, the stimulations lasted for 12 min (two fraction-times). In each experiment, three columns (parallel experiments) were used and 60 to 120 fractions were collected from each column. At the end of the experiments, the contents of the cells were extracted by passing hypotonic solution (10 mM HCl) through the columns. cAMP and IGF-II contents of the fractions were determined by RIA. Washout studies with cAMP and the used peptides were performed with radiolabeled compounds or by RIA measurements. Data from these studies indicate that the substances pass rapidly through the column -more than 90% passing within 1 min.
RIA results were further analysed with a dedicated computer program as described earlier (Csernus & Schally 1991) . Briefly: the program first separates the fractions containing basal concentrations of the secreted hormones from the response fraction using several iterations. From the values of the basal fractions, the statistical parameters of the baseline are determined. A fraction is considered as a response if it is larger or smaller than the 95% confidence limits of the baseline. Further statistical analysis is based on the Net Integral values (area of the response curve above the baseline) of the responses. In the figures, representative examples of two to six identical experiments, with visually the same results, are shown.
cAMP RIA
Immediately after collection, superfusion samples were acetylated by addition of 25 µl freshly prepared mixture of triethylamine and acetic anhydride (2 : 1) to 500 µl icecold aliquots of the medium fractions. Subsequently, the acetylated samples were kept frozen at 20 C until required for assay, usually in a few days. Duplicate samples of 100 µl acetylated medium, 200 µl PBS (0·05 M, pH=7·4), 100 µl antibody solution (anti-cAMP-NIDDK CV-27 at 1 :166 000 final dilution) and 100 µl tracer (15 000 c.p.m. in PBS) were incubated in borosilicate tubes. The 125 I-labelled tracer was prepared from tyrosylmethyl ester-cAMP (Sigma M 2257) using the lactoperoxidase method followed by HPLC purification on a Vydac C-18 column with a linear gradient of acetonitrile and aqueous 0·1% trifluoroacetic acid. Monoiodinated derivative was separated, aliquoted in PBS containing 10 g/l BSA and 70 µg/ml bacitracin, and stored at 70 C. Standards in the range 0·65-658 pg/tube were dissolved in superfusion medium and were acetylated together with the samples. After an overnight incubation at 4 C, the bound fraction was separated using a second antibody-polyethylene glycol method. The radioactivity was measured and RIA results were processed in a Micromedic Apex automatic gamma counter. The sensitivity of the assay was 1·2 pg/tube. Interassay and intra-assay coefficients of variation were 8·5% and 4·5%, respectively.
IGF-II RIA
Duplicate samples of 100 µl superfusion medium, 20 000 c.p.m. of radiolabeled IGF-II and the antibody were incubated in a total of 500 µl assay buffer (0·05 M phosphate buffer containing 0·2 g/l protamine, 0·2 g/l sodium azide and 0·5 g/l Tween 20, pH=7·6) in polypropylene tubes. Human recombinant IGF-II (Bachem California, Torrance, CA, USA) was radioiodinated by the lactoperoxidase method and purified by reverse-phase HPLC on a Vydac C18 column. Monoclonal antibody generated against rat IGF-II (Amano Enzymes USA, Troy, VA, USA; 10 µg/ml) was used at a final dilution of 1 : 14 000. This antibody cross-reacts 100% with human IGF-II and 10% with human IGF-I. The standards ranged from 2 to 1000 pg/tube. To each standard tube, 100 µl superfusion medium was added. Separation, counting and RIA processing were similar to that described for cAMP RIA. The sensitivity of the assay was 4·5 pg/tube. Interassay and intra-assay coefficients of variation were 10% and 8% respectively.
Results
cAMP response of cancer cells to pulsatile stimulations with GHRH, VIP and PACAP
Five million MDA-MB-468 human breast cancer cells were stimulated with 5 nM GHRH or 200 pM VIP for 12 min at 45-min intervals. The cells responded to the stimulation with a rapid, transient increase in release of cAMP into the effluent medium (Fig. 1) . The responses were reproducible although there were apparent signs of desensitization. After a similar stimulation with 2 µM forskolin, a stimulator of adenylate cyclase, a transient increase in cAMP release was also obtained (Fig. 1 , response F). The onset of the cAMP response to forskolin was somewhat slower than that to GHRH, VIP or PACAP-38. Hypotonic HCl extract at the end of the experiment contained cAMP concentrations well above baseline values, but with smaller Net Integral values than those obtained in response to GHRH or VIP.
To study the short-time desensitization of cancer cells to repeated stimulations, MDA-MB-468 cells were exposed repeatedly to 5 nM GHRH, 100 pM VIP or 500 pM PACAP-38 for 12 min in unequal (30-60 min) intervals in experiments similar to that described above (Fig. 2) . The three experiments shown in Fig. 2 were performed simultaneously, using the same number and batch of the cancer cells. A noticeable desensitization with partial functional recovery of cAMP release was found (Fig. 2) . Responses to all three peptides showed an overall tendency to decrease. The magnitude of the response was a function of interval between stimulations. The decrease was stronger after rapid repetition of stimulations (30 min), but an increase in response, compared with the previous one, was found when the lag between stimulations was longer. These observations were consistent in case of stimulations with GHRH ( Fig. 2a) , but responses to VIP did not strictly follow this pattern (Fig. 2b) . The cAMP response to a similar scheme of stimulations with PACAP-38 showed a very rapid desensitization with only a slight, temporary tendency for recovery (Fig. 2c) . By the middle of the experiment, the cAMP responsiveness of the cells to PACAP-38 disappeared completely. Net Integral values of the responses to the first stimulation with GHRH, VIP and PACAP-38 were 12·1 ng, 9·56 ng and 5·81 ng, whereas Net Integral values of the peaks containing the HCl extract were 6·50 ng, 2·47 ng and 2·33 ng, respectively (Fig. 2) .
cAMP responses to stimulations of the cancer cells with GHRH, VIP and PACAP-38 were dose-dependent. However, because of the rapid desensitization, the actual size of the responses was a function of both the dose and the parameters (timing and size) of the previous stimulation. This is why, within one experiment, no linear dose-response curve could be obtained in our system. The dose-response relationship of GHRH-and VIP-induced cAMP release was evaluated by mathematical analysis of the Net Integral values of the first responses in several experiments. cAMP release was increased by 17·71 1·52 ng, 8·79 0·58 ng and 3·81 0·34 ng after 12-min pulsatile stimulations with 10 nM, 5 nM and 2·5 nM GHRH, respectively. Similarly, the cells responded with 32·66 1·63 ng, 20·41 1·63 ng, 10·78 1·36 ng, 5·14 0·41 ng, 1·14 0·05 ng and 0·91 0·05 ng increases in cAMP release to 12-min stimulation with 5 nM, 1 nM, 0·2 nM, 0·1 nM, 50 pM and 20 pM VIP, respectively. The lowest doses of GHRH, VIP and PACAP-38 that resulted in a significant increase in cAMP release from MDA-MB-468 cells (concentration in the fraction exceeding the upper 95% confidence limit of the baseline) were 500 pM, 20 pM and 50 pM, respectively.
In addition to MDA-MB-468, several other human cancer cells were exposed to different doses of GHRH, VIP, PACAP-38, secretin, glucagon and NPY in a superfusion system. The cell types and their relative cAMP responsiveness to GHRH, VIP and PACAP-38 are shown in Table 1 . Hypotonic HCl extract of the every cell types contained various amounts of cAMP (1·01-18·4 ng, average Net Integral values). cAMP concentrations in the baseline fractions were above the limit of sensitivity of the RIA (12 pg/ml) in all cases. In none of the cell lines tested in our system, however, was there an increase in cAMP release in response to 12-min stimulations with up to 100 nM concentration of secretin, glucagon and NPY (data not shown).
cAMP response of the cancer cells to prolonged stimulation with GHRH and VIP
After a short, 12-min stimulation, MDA-MB-468 cells were exposed to 5 nM GHRH or 100 pM VIP for 92 min (Fig. 3) . Because we previously found, when studying GH release from pituitaries (Csernus & Schally 1991 ) that, in our system, GHRH is rapidly inactivated in the oxygenated warm medium, fresh solutions of GHRH and VIP were made from stock every 12 min. The stimulations induced a rapid increase in cAMP concentration in the medium which was maintained until the end of the exposure and returned to the baseline thereafter. The response was biphasic in the case of both GHRH and VIP: the initial high values then declined, but about 1 h after the start of the exposure, a secondary, smaller peak occurred; in the case of VIP, this secondary peak was substantially lower than the initial peak, indicating a more rapid desensitization. A greatly diminished cAMP response to 12 min stimulation with 5 nM GHRH after a long exposure to VIP also indicated that the cAMPsynthesizing machinery of the cells exposed to VIP was more downregulated than that of GHRH-exposed cells (compare last responses in Fig. 3a and b) . Similar response curves were obtained in identical experiments with SW-1990 and PC-3 cells (data not shown).
Effect of agonistic and antagonistic VIP analogs on cAMP release from cancer cells
MDA-MB-468 cells were exposed repeatedly to VIP 1 receptor-specific agonists (Lys 15 ,Arg 16 ,Leu
27
-VIP(1-7)/ GHRH(8-27)) in 5 nM concentration for 12 min at 45-min intervals (Fig. 4) . The agonist induced a rapid, temporary increase in cAMP concentration in the effluent medium. The responses and the tendency of desensitization were similar to that induced by 100 pM VIP under identical conditions. VIP 1 receptor-specific antagonistic analog PG-97-269, given for 12 min before and during the third stimulation at 200 nM concentration, caused a complete blockade of the cAMP response (Fig. 4) . The consecutive responses to the agonist, however, were apparently not affected, indicating that, under these experimental conditions, the effect of the antagonist is very brief. The effect of the antagonistic analog of VIP, PG-97-269, on GHRH, VIP, and PACAP-induced cAMP release from MDA-MB-468 cells was also investigated in the superfusion system. In an experimental procedure similar to that described above, MDA-MB-468 cells were stimulated repeatedly with 5 nM GHRH, 100 pM VIP or 500 pM PACAP. During the third stimulation and for 12 min preceding it, 100 nM VIP antagonist PG-97-269 was also added (Fig. 5) . The antagonist caused a complete blockade of the cAMP release, followed by a gradual recovery of the responsiveness to consecutive stimuli. The VIP antagonist showed a longer-lasting inhibitory effect on the cAMP release induced by GHRH, VIP and PACAP than on the response to the VIP agonist. Interestingly, we found the most complete recovery of responsiveness in the case of PACAP (Fig. 5c) , which, without the application of the antagonist, showed a complete desensitization (Fig. 2c) . This effect was consistent through several similarly designed experiments.
The effects of the VIP antagonist on cAMP release induced by prolonged stimulation with GHRH and VIP was also analysed. After a 12-min pulsatile stimulus with 5 nM GHRH or 200 pM VIP, the cells were stimulated with the same peptide for 168 min (a fresh solution being used every 12 min), followed by repeating the first stimulation 30 min later. Somatostatin in 20 nM concentration and PG-97-269 VIP antagonist at 100 nM concentration were also added 24 min and 60 min after the onset of the stimulus, respectively (Fig. 6 ). Before addition of the antagonist, the response curves were similar to biphasic responses on Fig. 3 . Somatostatin showed no apparent effect on GHRH-induced cAMP release and only a marginal effect on VIP-induced cAMP release. The antagonistic analog of VIP rapidly inhibited the cAMP release, and only a marginal recovery of cAMP responsiveness was found by the end of the stimulation with both GHRH and VIP. The cAMP response to pulsatile stimulations with GHRH or VIP was greatly attenuated when either stimulant was administered after a long-lasting stimulation with the same substance.
Effect of intracellular signal-transduction-affecting drug on GHRH-and VIP-induced cAMP release from cancer cells
Forskolin, a stimulator of adenylate cyclase, was active in our system. Except for H-23 lung cancer cells, all the tested cells responded to 12-min stimulations with 2 µM forskolin (0·26-15·4 ng cAMP, average Net Integral values). The cAMP response to stimulation with 2 µM forskolin for 12 min was subsequently used for functional standardization of the columns in this series of experiments.
PTX, which uncouples adenylate cyclase from Gi-and Go-proteins, did not reduce the cAMP response to GHRH, VIP (Fig. 7a) , and PACAP-38 (similar conditions, data not shown) in MDA-MB-468 and SW-1990 cells (data not shown). The adenylate cyclase inhibitor, SQ-22536, in 100 µM concentration also failed to inhibit GHRH-and VIP-induced cAMP release from MDA-MB 468 cells (data not shown). The novel adenylate cyclase inhibitor, MDL-12330A (Lippe & Ardizzone 1991) , in 125 µM concentration, however, showed a long-term inhibition of both GHRH-and VIP-induced cAMP release in MDA-MB-468 (Fig. 7b) and SW-1990 cells (data not shown). MDL-12330A greatly diminished both the cAMP response to forskolin and the cAMP content of hypotonic HCl extract at the end of the experiment indicating that MDL-12330A, unlike PTX, permanently blocked the cAMP-synthesizing machinery.
IGF-II secretion from human cancer cells in vitro
In most of the experiments described above, the IGF-II content of the superfusion medium was also determined. The average basal release of IGF-II into the superfusion medium by most of the cell lines was above the limit of sensitivity of our IGF-II RIA (45 pg/ml). Except for that from H-23 cells, the hypotonic HCl extract at the end of the experiment had a significantly greater IGF-II content than the baseline, indicating considerable intracellular IGF-II reserve (Table 2) . A short-term, pulsatile stimulation of IGF-II secretion from human cancer cells could not be achieved in our superfusion studies with any of the compounds used for stimulating cAMP release from the cells. However, an increase in the extracellular K + concentration (50 mM for 6 min) induced a sharp, transient increase in IGF-II concentration in the medium (data not shown). This response was similar to that of peptide hormone-producing glands (Csernus & Schally 1991) . The cAMP content of the medium did not change after the increase in extracellular K + concentration.
Discussion
Studies on cAMP release from explanted cells in a superfusion system are useful for investigating intracellular mechanisms of hormone release from endocrine tissues (Horvath et al. 1995a , b, Rekasi et al. 1998 . The mechanism by which cAMP leaves the cell and moves into the extracellular space, in our case the medium, is not clear. Concentrations of cAMP in the effluent medium were found to be proportional to the intracellular cAMP concentration in several endocrine and cancer cells, and are (12) ND, not determined; se , cultured in serum-free medium.
V CSERNUS and others · GHRH, cAMP and cancer cellsapparently unaffected by cAMP-independent specific and non-specific stimulators or inhibitors of hormone release (our unpublished observations). An immediate increase (occurring within seconds) in cAMP concentration in the tissue culture medium follows any intracellular metabolic changes that activate cAMP synthesis. No apparent exocytotic activity, such as concomitant hormone secretion, is required for the release of cAMP from the cells. Also, profound exocytosis, such as a stimulation of hormone secretion, induced in any specific or non-specific fashion that does not enhance cAMP synthesis, does not increase cAMP concentration in the medium. Hypotonic HCl extracts of the cells, in most cases, contain cAMP concentrations significantly greater than baseline values. In contrast to peptide hormones, most of the cAMP in the cell extract may not come from an intracellular 'reserve', but it is a rapid product of a non-specific stimulation of the dying cells. Thus the concentration of cAMP in the extract may indicate the momentary functional capacity of the cAMP-synthesizing intracellular machinery. The concentration of the peptides used in our study was based on several factors. Because of the very rapid desensitization, no accurate half-maximal dose could be calculated. After preliminary tests with a wide range of concentrations, we selected a concentration range of each hormone that was (1) high enough to give a significant response-peak concentration 20-50 times higher than the baseline, and (2) low enough to keep the exhaustion of the cells within sensible limits. The physiological concentration of the peptides could not be determined easily, as GHRH, VIP and PACAP act primarily as paracrine/ autocrine control substances. Thus their easily measurable serum concentration is very different from the local tissue concentration. On the basis of data in the literature (Shibasaki et al. 1984 , Thorner et al. 1985 , Frohman et al. 1986 , 1989b , Losa et al. 1990 , Ciampani et al. 1992 , Kahan et al. 1999 and in vitro bioassays of pituitary cells (Csernus & Schally 1991) , the physiological concentration of these peptide can be in the range 100 pM to 10 nM. Therefore, the concentration that we used may be considered physiological.
As our results reveal, GHRH in physiological concentrations directly stimulates cAMP synthesis by various human cancer cell lines, such as MDA-MB-468 and ZR-75-1 breast cancers, Capan-2 and SW-1990 pancreatic cancers, PC-3 prostate cancer, OV-1063 ovarian cancer and LoVo colorectal cancer. The response is rapid and dose-dependent, indicating that the receptor(s) intimately related to adenylate cyclase is involved.
The physiological significance of the GHRH-induced release of cAMP from human cancer cells is not clear. In most cells, cAMP is a potent second messenger, facilitating protein synthesis and controlling a wide variety of other intracellular functions, including some of those required for cell growth. These functions may encompass the synthesis and release of IGF-II. Earlier, we reported that several human cancer cell lines express IGF-II mRNA and secrete IGF-II into the tissue culture medium (Csernus et al. 1999a) . Antagonistic analogs of GHRH, which appear to inhibit the effect of GHRH on cancer cells (Pinski et al. 1995 , Jungwirth et al. 1997a , Schally et al. 1998 , reduce IGF-II levels and IGF-II mRNA synthesis in cultured human cancer cell lines (Csernus et al. 1999a) . Many cell lines in our present study also produced IGF-II in the superfusion system (Table 2) . Increased extracellular K + concentration, a widely used non-specific stimulus for peptide hormone release (Csernus & Schally 1991) , also induced pulsatile liberation of IGF-II from these cells (Table 2 ). However, pulsatile stimulation with GHRH, VIP and PACAP did not result in a short-term IGF-II response. These results suggest that cAMP may stimulate the synthesis and not the release of IGF-II. The changes in the level of synthesis of IGF-II may be apparent within hours, which is much longer than the time-frame of the superfusion experiments performed in this study.
To accomplish the cAMP-activating effect, GHRH may share receptor(s) with VIP and PACAP (Laburthe et al. 1996 , Van Rampelbergh et al. 1997 . These peptides show extensive homologies in amino acid sequences, and overlapping functions (Ciampani et al. 1992 , Inagaki et al. 1996 , Vertongen et al. 1996 , Parkman et al. 1997a . Potent VIP agonists and antagonists also show extensive structural homology with GHRH(1-29) (Gourlet et al. 1997a, b) . Interactions between the GHRH-GH axis and VIP in vivo have also been described (Carlsson et al. 1996 , Hyde et al. 1996 : the levels of VIP and its mRNA were greatly decreased in transgenic mice over-expressing hGHRH (Hyde et al. 1996) , and a VIP antagonist was found to decrease PACAP-38-induced pancreatic blood flow (Carlsson et al. 1996) . Thus, GHRH may be a member of the peptide hormone family that, in response to local environmental conditions, modulates the activities and growth of normal and malignant tissues through paracrine/autocrine mechanisms. The receptors involved in GHRH-induced cAMP release from the tumor cells remain to be identified. As adenylate cyclase of the GHRH-sensitive cancer cells can be also stimulated by VIP and PACAP, it is possible that a single receptor with different affinity to GHRH, VIP and PACAP may be involved. The view of a single receptor is supported by some of our results, such as the similarity of responses to MDL-12330A (a complete blockade, Fig. 7b ) and to PTX and SQ-22536 (lack of effect). In addition, the responses to GHRH, VIP and PACAP can be inhibited by VIP 1 receptor-specific antagonist. The tumor cells were also sensitive to VIP 1 receptor-specific agonist, although in a concentration about 50 times greater than that of VIP (5 nM compared with 100 pM, Figs 4 and 5b) . However, the marked difference in desensitization after the exposure to the three peptides may indicate the presence of different receptors. Similarly, the differences in relative sensitivities of cAMP synthesis to stimulation with GHRH, VIP and PACAP (Table 1) may likewise indicate multiple receptors (with different levels of expression among cancers). The diversity in the desensitizing capacity of the peptides cannot be explained by differences in the exhaustion of the cAMP-synthesizing machinery of the cells, because a lower amount of cAMP was released from the PACAPstimulated cells than from those exposed to GHRH or VIP, indicating that the decrease in the responsiveness was due to downregulation rather than to depletion.
The receptor(s) in question may be a known member(s) of the GHRH, VIP, and PACAP receptor family, or unknown. However, our attempts to demonstrate mRNA expression for pituitary GHRH, VIP 1 , VIP 2 or PACAP-1 receptors in cancer cells found to be sensitive to GHRH have been unsuccessful so far (unpublished observations). GH and cAMP release from pituitary GH cells in our system can be blocked with very low (<100 pM) concentrations of somatostatin (Csernus & Schally 1991) . The fact that somatostatin did not inhibit GHRH-induced cAMP release from the cancer cells even in a concentration of 20 nM (Fig. 6 ) may also indicate that, in this case, a pituitary-type GHRH receptor complex is not involved. Participation of the PACAP-II/VIP 1 receptor can also be excluded, as the adenylate cyclaseactivating effect of the PACAP-II/VIP 1 receptor, unlike that in our experiment (Fig. 7) , can be blocked with PTX (Van Rampelbergh et al. 1997) . PACAP-I receptor has a negligible affinity for the VIP antagonist, PG-97-269 (Gourlet et al. 1997a) , which was very effective in our system (Figs 4-6). Our observation that relatively high degree of functional recovery from desensitization was experienced after administration of VIP antagonist (Fig. 5) can be explained by a combination of two factors. During the exposure to the antagonist, the cell was relieved of the stimulatory effect of GHRH, VIP or PACAP, thus its responsiveness gradually recovered. By the time the antagonist was cleared from the receptors, the stimulations with VIP or PACAP resulted in restored responses. Our findings that pulsatile administration of secretin, glucagon, and NPY had no effect on cAMP secretion from the cancer cells add further data on receptor specificity. These observations suggest that an unknown receptor may be involved in mediating GHRH-induced cAMP release from some human cancer cells. Studies to identify this receptor and its mRNA are in progress in our laboratory.
Collectively, our findings indicate that GHRH, VIP and PACAP exert a direct stimulatory effect on cAMP synthesis of some human cancers. Most of these cells also produce IGF-II. These data, supported by our earlier observation that antagonistic analogs of GHRH inhibit IGF-II and its mRNA (Csernus et al. 1999a) , suggest that autocrine/paracrine peptides of the GHRH-VIP-PACAP family may exert direct regulatory effects on the growth of cancer cells, through the activation of cAMP and IGF-II systems. The interference with this action produced by antagonistic analogs of GHRH may provide a new approach to tumor control. 
